Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Immunological Assays used to Support Efficacy of Zika Virus Vaccines.

Eckels KH, De La Barrera RA, Putnak JR.

Trop Med Infect Dis. 2019 Jun 28;4(3). pii: E97. doi: 10.3390/tropicalmed4030097. Review.

2.

Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.

McCracken MK, Gromowski GD, Friberg HL, Lin X, Abbink P, De La Barrera R, Eckles KH, Garver LS, Boyd M, Jetton D, Barouch DH, Wise MC, Lewis BS, Currier JR, Modjarrad K, Milazzo M, Liu M, Mullins AB, Putnak JR, Michael NL, Jarman RG, Thomas SJ.

PLoS Pathog. 2017 Aug 3;13(8):e1006487. doi: 10.1371/journal.ppat.1006487. eCollection 2017 Aug.

3.

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.

Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R, Simmons M, Jarman RG, Currier JR, Friberg H, Danko JR, Teneza-Mora NC, Putnak JR, Eckels KH, Thomas SJ.

Am J Trop Med Hyg. 2015 Sep;93(3):454-460. doi: 10.4269/ajtmh.14-0819. Epub 2015 Jul 6.

4.

An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.

Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, Toussaint JF, Mossman S, Innis BL, Schmidt A, Malice MP, Festraets P, Warter L, Putnak JR, Eckels KH.

Am J Trop Med Hyg. 2015 Apr;92(4):698-708. doi: 10.4269/ajtmh.14-0268. Epub 2015 Feb 2.

5.

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.

Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP Jr, Statler JD, Innis BL.

J Infect Dis. 2013 Mar 1;207(5):700-8. doi: 10.1093/infdis/jis744. Epub 2012 Dec 5.

PMID:
23225894
6.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.

Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, Barrera Rde L, Mammen MP Jr.

Am J Trop Med Hyg. 2011 Aug;85(2):341-51. doi: 10.4269/ajtmh.2011.10-0501.

7.

Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.

Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T.

Vaccine. 2010 Mar 24;28(15):2705-15. doi: 10.1016/j.vaccine.2010.01.022. Epub 2010 Jan 22.

8.

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R.

Hum Vaccin. 2009 Jan-Feb;5(1):33-40. Epub 2009 Jan 27.

PMID:
18670195
9.

Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies.

Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W.

Am J Trop Med Hyg. 2008 Jul;79(1):115-22.

PMID:
18606774
10.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP Jr.

Am J Trop Med Hyg. 2008 Mar;78(3):426-33.

PMID:
18337339
11.

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ, Endy TP.

J Infect Dis. 2006 Jun 15;193(12):1658-65. Epub 2006 May 9.

PMID:
16703509
12.

Atypical antibody responses in dengue vaccine recipients.

Kanesa-Thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, Innis BL, Edelman R.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):32-8. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740953
13.

Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.

Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, Innis BL.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):24-31.

PMID:
14740952
14.

Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.

Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke CH Jr.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):17-23. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740951
15.

Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines.

Kanesa-Thasan N, Putnak JR, Mangiafico JA, Saluzzo JE, Ludwig GV.

Am J Trop Med Hyg. 2002 Feb;66(2):115-6.

PMID:
12135278
16.

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, Zhao B, Olson RA, Kim SO, Yoo WD, Towle AC, Vaughn DW, Innis BL, Eckels KH.

Vaccine. 2001 Aug 14;19(31):4557-65.

PMID:
11483284
17.

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.

Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr.

Vaccine. 2001 Apr 30;19(23-24):3179-88.

PMID:
11312014
18.

Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.

Sardelis MR, Edelman R, Klein TA, Innis BL, Putnak JR, Jones JW, Turell MJ.

Am J Trop Med Hyg. 2000 Jun;62(6):698-701.

PMID:
11304057
19.

A putative cellular receptor for dengue viruses.

Putnak JR, Kanesa-Thasan N, Innis BL.

Nat Med. 1997 Aug;3(8):828-9. No abstract available.

PMID:
9256265
20.
21.

New approaches to flavivirus vaccine development.

Schlesinger JJ, Putnak JR, Eckels KH.

Biotechnology. 1992;20:289-307. Review. No abstract available.

PMID:
1318137
22.

The dengue viruses.

Henchal EA, Putnak JR.

Clin Microbiol Rev. 1990 Oct;3(4):376-96. Review.

24.

Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody.

Schlesinger JJ, Brandriss MW, Putnak JR, Walsh EE.

J Gen Virol. 1990 Mar;71 ( Pt 3):593-9.

PMID:
2138210
25.

Morphogenesis of flaviviruses.

Hase T, Summers PL, Eckels KH, Putnak JR.

Subcell Biochem. 1989;15:275-305. Review. No abstract available.

PMID:
2552624
26.

Functional and antigenic domains of the dengue-2 virus nonstructural glycoprotein NS-1.

Putnak JR, Charles PC, Padmanabhan R, Irie K, Hoke CH, Burke DS.

Virology. 1988 Mar;163(1):93-103.

PMID:
2964755
27.

Use of temperature-sensitive mutants to study the morphogenesis of poliovirus.

Drescher-Lincoln CK, Putnak JR, Phillips BA.

Virology. 1983 Apr 15;126(1):301-16.

PMID:
6302987
30.

Picornaviral structure and assembly.

Putnak JR, Phillips BA.

Microbiol Rev. 1981 Jun;45(2):287-315. Review. No abstract available.

31.

Serodiagnosis of hepatitis B virus infection by antibody to core antigen.

Irwin GR, Allen RG, Segal HG, Allen AM, Putnak JR, Cannon HG, Top FH Jr.

J Infect Dis. 1977 Jul;136(1):31-6.

PMID:
560416

Supplemental Content

Loading ...
Support Center